All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
In the November 2017 issue of Haematologica, Pieternella Lugtenburg of the Erasmus MC Cancer Institute in Rotterdam, Netherlands and colleagues published results from the MabEase phase IIIb clinical trial in first-line diffuse large B-cell lymphoma (DLBCL). In this multicenter, randomized, open-label study, treatment-naïve patients with DLBCL were randomized 2:1 to receive either subcutaneous rituximab (intravenous 375 mg/m2 cycle 1; subcutaneous 1,400 mg cycles 2–8) or intravenous rituximab (375 mg/m2 cycles 1–8) plus cyclophosphamide, doxorubicin, vincristine, and prednisone every 14 or 21 days (NCT01649856). The primary endpoint was investigator-assessed complete response (Cr)/unconfirmed complete response (CRu). Secondary endpoints included safety, treatment satisfaction, time savings, and survival. The objective of this study was to investigate the efficacy, safety and patient satisfaction of rituximab SC compared to the IV formulation as part of a rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen.
The MabEase study achieved its goal of excluding major differences in efficacy and safety between rituximab SC and IV treatment arms in newly diagnosed DLBCL patients treated with R-CHOP. This has been underscored by the primary endpoint data which indicated similar efficacy of the rituximab SC and IV formulations in the overall study population. Of interest, the CR/CRu rates in this study (SC, 50.6%; IV, 42.4%) were lower compared to historical data, which may be attributed to the approximately 18% of patients discontinued study treatment before the end of cycle 8. However, among the SC and IV patients who did complete all eight cycles of induction, the CR/CRu rates were 57% and 47%, respectively. Despite the relatively lower CR rate, the overall response rate in this study was similar to observations in previous studies. In addition, similar safety profiles were observed in the SC and IV arms, no new safety signals, and a rate of treatment-related deaths that was comparable to those found in other studies. The most frequent SAE in this study was febrile neutropenia, although there was no difference between groups in rates of treatment discontinuation due to AEs or infections. Given that the MabEase study showed no major differences in efficacy and safety between treatment arms, coupled with higher RASQ scores in the rituximab SC arm, it’s rational to suggest that the results of this study support the use of rituximab SC in treatment-naïve patients with DLBCL.
Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce treatment burden. MabEase (clinicaltrials.gov Identifier: 01649856) examined efficacy, safety and patient satisfaction with subcutaneous rituximab plus chemotherapy in treatment-naïve patients with diffuse large B-cell lymphoma. Patients were randomized 2:1 to subcutaneous rituximab (intravenous 375 mg/m cycle 1; subcutaneous 1,400 mg cycles 2–8) or intravenous rituximab (375 mg/m cycles 1–8) plus cyclophosphamide, doxorubicin, vincristine, and prednisone every 14 or 21 days. The primary endpoint was investigator-assessed complete response/unconfirmed complete response. Secondary endpoints included safety, treatment satisfaction (Cancer Treatment Satisfaction Questionnaire and Rituximab Administration Satisfaction Questionnaire), time savings, and survival. Of 576 randomized patients, 572 (378 subcutaneous; 194 intravenous) received treatment. End of induction complete response/unconfirmed complete response rates were 50.6% (subcutaneous) and 42.4% (intravenous). After a median 35 months, median overall, event-free and progression-free survivals were not reached. Grade ≥3 adverse events (subcutaneous 58.3%; intravenous 54.3%) and administration-related adverse events (both groups 21%) were similar between arms. Injection-site reactions were more common with subcutaneous injections (5.7% versus 0%, respectively). Rituximab Administration Satisfaction Questionnaire scores for ‘impact on activities of daily living’, ‘convenience’, and ‘satisfaction’ were improved with subcutaneous versus intravenous injections; Cancer Therapy Satisfaction Questionnaire scores were similar between arms. Median administration time (6 minutes vs. 2.6 to 3.0 hours), chair/bed and overall hospital times were shorter with subcutaneous versus intravenous rituximab. Overall, subcutaneous and intravenous rituximab had similar efficacy and safety, with improved patient satisfaction and time savings.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox